Livedoid vasculopathy as a coagulation disorder

Autoimmunity Reviews

Volumn 10, Issue 6, 2011, Pages 353-360

  Criado, Paulo Ricardo ^a   Rivitti, Evandro Ararigboia ^a   Sotto, Mirian Nacagami ^a   de Carvalho, Jozélio Freire ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Endothelium; Fibrin; Heparin; Leg ulcer; Livedo reticularis; Thrombin; Thrombophilia; Thrombosis; Vasculitis; Warfarin

Indexed keywords

CYANOCOBALAMIN; DALTEPARIN; ENOXAPARIN; FOLIC ACID; HEPARIN; METHYLPREDNISOLONE; NADROPARIN; PENTOXIFYLLINE; PYRIDOXINE; WARFARIN;

ANTICOAGULANT THERAPY; BLOOD CLOTTING DISORDER; DIFFERENTIAL DIAGNOSIS; ERYTHEMA; HEPARINIZATION; HISTOPATHOLOGY; HUMAN; PAPULAR SKIN DISEASE; REVIEW; SKIN BLOOD VESSEL DISORDER; SKIN SCAR; SKIN ULCER; THROMBOPHILIA;

BLOOD COAGULATION DISORDERS; HUMANS; LIVEDO RETICULARIS;

EID: 79953164404     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.11.008     Document Type: Review

References (91)

1. Papi M., Didonia B., Frezzolini A., Di Giulto S., De Mattets W., Del Principe D., et al. Livedo vasculopathy vs. small vessel cutaneous vasculitis. Arch Dermatol 1998, 134:447-452.
2. Criado P.R., Lavôr I.M., Landman G. Vasculopatia livedóide associada a anticorpos anticardiolipina. Rev Bras Clin Terap 2001, 27(5):195-198.
3. Bard J.W., Winkelmann R.K. Livedo vasculitis: segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967, 96:489-499.
4. Feldaker M., Hines E.A., Kierland R.R. Livedo reticularis with summer ulcerations. Arch Dermatol 1955, 72:31-42.
5. Poletti E.D., Muñoz Sandoval N.R., Moreno González J.L., Santacruz Torres A. Vasculopatía livedoide: significado actual. Comunicación de dos casos. Dermatol Rev Mex 2008, 52(4):175-181.
6. Stevanovic D.V. Atrophie blanche: a sign of dermal blood occlusion. Arch Dermatol 1974, 109:858-862.
7. Winkelmann R.K., Schroeter A.L., Kierland R.R., Ryan T.M. Clinical studies of livedoid vasculitis (segmental hyalinizing vasculitis). Mayo Clin Proc 1974, 49:746-750.
8. Di Giacomo T.B., Hussein T.P., Souza D.G., Criado P.R. Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs-a prospective study. J Eur Acad Dermatol Venereol 2010, 24(11):1340-1346.
9. Jorge A.D., Fantini B.C., Rivitti E.A., Benabou J.E., Vasconcellos C., Criado P.R. Análise da freqüência de trombofilia em pacientes com atrofia branca de Milian. An Bras Dermatol 2007, 82(1):25-33.
10. Toth C., Trotter M., Clark A., Zochodne D. Mononeuropathy multiplex in association with livedoid vasculitis. Muscle Nerve 2003, 28(5):634-639.
11. Browing C.E., Callen J.P. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006, 142:75-78.
12. Cocuroccia B., Tonanzi T., Menaguale G., Fazio M., Girolomoni G. Livedoid vasculopathy and skin ulcers in patients with inherited thrombophilia. Eur J Dermatol 2002, 12:360-363.
13. Gibson G.E., Li H., Pittelkow M.R. Homocysteinemia and livedoid vasculitis. J Am Acad Dermatol 1999, 40(Pt1):279-281.
14. Oh Y.B., Jun J.B., Kim C.K., Lee C.W., Park C.K., Kim T.Y., et al. Mixed connective tissue disease associated with skin defects of livedoid vasculitis. Clin Rheumatol 2000, 19:381-384.
15. Chen K.R., Toyohara A., Suzuki A., Miyakawa S. Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 2002, 147:905-913.
16. Maessen-Visch M.B., Koedam M.I., Hamulyák K., Neumann H.A. Atrophie blanche. Int J Dermatol 1999, 38(3):161-172.
17. Franco R.F. Trombofilias hereditarias. Medicina (Ribeirao Preto) 2001, 34:248-257.
18. Deng A., Gocke C.D., Hess J., Heyman M., Paltiel M., Gaspari A. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006, 142(11):1466-1469.
19. Goerge T., Weishaupt C., Metze D., Nowak-Göttl U., Sunderkötter C., Walsh J.S., Schneider S.W. Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: prompt response to continuous low-molecular-weight heparin. Arch Dermatol 2010, 146(8):927-928.
20. Hesse G., Kutzner H. Therapeutic use of low molecular weight heparin for capillaritis alba. Phlebologie 2008, 37:259-265.
21. Boyvat A., Kundakçi N., Babikir M.O.A., Gürgey E. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 2000, 143:840-842.
22. Klein K.L., Pittelkow M.R. Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc 1992, 67:923-933.
23. Peschen M., Rogers A.A., Chen W.Y., Vanscheidt W. Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency. Acta DermVenereol 2000, 80:162-166.
24. Pizzo S.V., Murray J.C., Gonias S.L. Atrophie blanche. A disorder associated with defective release of tissue plasminogen activator. Arch Pathol Lab Med 1986, 110:517-519.
25. McCalmont C.S., McCalmont T.H., Jorizzo J.L., et al. Livedo vasculitis: vasculitis or thrombotic vasculopathy?. Clin Exp Dermatol 1992, 17:4-8.
26. Serra S., Saavedra M.J., Salvador M.J., Reis J.P., Walsh J.S. Livedoid vasculitis in a patient with antiphospholipid syndrome. Acta Reumatol Port 2010, 35(2):249-253.
27. Grasland A., Crickx B., Blanc M., Pouchot J., Vinceneux P. Livedoid vasculopathy (white atrophy) associated with anticardiolipin antibodies. Ann Med Interne (Paris) 2000, 151(5):408-410.
28. Sopeña B., Pérez-Rodríguez M.T., Rivera A., Ortiz-Rey J.A., Lamas J., Freire-Dapena M.C. Livedoid vasculopathy and recurrent thrombosis in a patient with lupus: seronegative antiphospholipid syndrome?. Lupus 2010, 19(11):1340-1343.
29. Boyvat A., Kundakçi N., Babikir M.O.A., Gürgey E. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol 2000, 143:840-842.
30. Biedermann T., Flaig M.J., Sander C.A. Livedoid vasculopathy in a patient with factor V mutation (Leiden). J Cutan Pathol 2000, 27(8):410-412.
31. Hairston B.R., Davis M.D., Pittelkow M.R., Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol 2006, 142(11):1413-1418.
32. Gotlib J., Kohler S., Reicherter P., Oro A.E., Zehnder J.L. Heterozygous prothrombin G20210A gene mutation in a patient with livedoid vasculitis. Arch Dermatol 2003, 139(8):1081-1083.
33. Khenifer S., Thomas L., Balme B., Dalle S. Livedoid vasculiltis associated with a double heterozygous Factor V Leiden and prothrombin G20210A gene mutations. Clin Exp Dermatol 2009, 34(8):e811-e813.
34. Hegemann B., Helmbold P., Marsch W.C. Livedoid vasculitis with ulcerations: the role of antithrombin III deficiency and its therapeutic consequences. Arch Dermatol 2002, 138(6):841-842.
35. Tran M.D., Bécherel P.A., Cordel N., Piette J.C., Francès C. "Idiopathic" white atrophy. Ann Dermatol Vénéréol 2000, 128(10 Pt 1):1003-1007.
36. Klein K.L., Pittelkow M.R. Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc 1992, 67(10):923-933.
37. Wakelin S.H., Ellis J.P., Black M.M. Livedoid vasculitis with anticardiolipin antibodies: improvement with danazol. Br J Dermatol 1998, 139(5):935-937.
38. Acland K.M., Darvay A., Wakelin S.H., Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?. Br J Dermatol 1999, 140(1):131-135.
39. Magy N., Algros M.P., Racadot E., Gil H., Kantelip B., Dupond J.L. Liveoid vasculopathy with combined thrombophilia: efficacy of iloprost. Rev Méd Interne 2002, 23(6):554-557.
40. Calamia K.T., Balabanova M., Perniciaro C., Walsh J.S. Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation. J Am Acad Dermatol 2002, 46(1):133-137.
41. Hairston B.R., Davis M.D., Gibson L.E., Drage L.A. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol 2003, 139(8):987-990.
42. Lewerenz V., Burchardt T., Büchau A., Ruzicka T., Megahed M. Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome. Hautarzt 2004, 55(4):379-381.
43. Juan W.H., Chan Y.S., Lee J.C., Yang L.C., Hong H.S., Yang C.H. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy. Br J Dermatol 2006, 154(2):251-255.
44. Meiss F., Marsch W.C., Fischer M. Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences. Eur J Dermatol 2006, 16(2):159-162.
45. Amato L., Chiarini C., Berti S., Massi D., Fabbri P. Idiopathic atrophie blanche. Skinmed 2006, 5(3):151-154.
46. Rampf J., Sunderkötter C., Hirschfeld G., Scharffetter-Kochanek K., Weiss J.M. Methylenetetrahydrofolate reductase polymorphism associated with moderate hyperhomocysteinaemia in a patient with livedo vasculopathy: treatment with vitamin supplementation and low molecular weight heparin. Br J Dermatol 2006, 155(4):850-852.
47. Mimouni D., Ng P.P., Rencic A., Nikolskaia O.V., Bernstein B.D., Nousari H.C. Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche. Br J Dermatol 2003, 148(4):789-794.
48. Cardoso R., Gonçalo M., Tellechea O., Maia R., Borges C., Silva J.A., et al. Livedoid vasculopathy and hypercoagulability in a patient with primary Sjögren's syndrome. Int J Dermatol 2007, 46(4):431-434.
49. Kawakami T., Kawasaki K., Mizoguchi M., Soma Y. Therapeutic effect of lipoprostaglandin E1 on livedoid vasculitis associated with essential cryoglobulinaemia. Br J Dermatol 2007, 157(5):1051-1053.
50. Anavekar N.S., Kelly R. Heterozygous prothrombin gene mutation associated with livedoid vasculopathy. Australas J Dermatol 2007, 48(2):120-123.
51. Davis M.D., Wysokinski W.E. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: response to warfarin. J Am Acad Dermatol 2008, 58(3):512-515.
52. Irani-Hakime N.A., Stephan F., Kreidy R., Jureidini I., Almawi W.Y. Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity. J Thromb Thrombolysis 2008, 26(1):31-34.
53. Kavala M., Kocaturk E., Zindanci I., Turkoglu Z., Altintas S. A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin. J Dermatol Treat 2008, 19(2):121-123.
54. Tsai T.F., Yang C.H., Chu C.Y., Liou Y.H., Hsiao W.C., Lin C.T., et al. Polymorphisms of MTHFR gene associated with livedoid vasculopathy in Taiwanese population. J Dermatol Sci 2009, 54(3):214-216.
55. Antunes J., Filipe P., André M., Fraga A., Miltenyi G., Marques Gomes M. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy. Acta Derm Venereol 2010, 90(1):91-92.
56. Osada S., Kimura Y., Kawana S. Case of livedoid vasculopathy with peripheral neuropathy successfully treated with low-dose warfarin. J Dermatol 2010, 37(1):98-101.
57. Tabata N., Oonami K., Ishibashi M., Yamazaki M. Livedo vasculopathy associated with IgM anti-phosphatidylserine-prothrombin complex antibody. Acta Derm Venereol 2010, 90(3):313-314.
58. Yang L.J., Chan H.L., Chen S.Y., et al. Atrophie blanche: a clinicopathological study of 27 patients. Chang Gung Med J 1991, 14:237-245.
59. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome., 60 Asherson RA. Autoimmun Rev 2006 Dec, 6(2):76-80.
60. Jorizzo J.L. Livedoid vasculopathy. What is it?. Arch Dermatol 1998, 134:491-493.
61. Callen J.P. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. Arch Dermatol 2006, 142(11):1481-1482.
62. Winkler U.H. Effects of androgens on haemostasis. Maturitas 1996, 24(3):147-155.
63. Hsiao G.H., Chiu H.C. Livedoid vasculitis. Response to low-dose danazol. Arch Dermatol 1996, 132(7):749-751.
64. Hsiao G.H., Chiu H.C. Low-dose danazol in the treatment of livedoid vasculitis. Dermatology 1997, 194(3):251-255.
65. Drucker C.R., Duncan W.C. Antiplatelet therapy in atrophie blanche and livedo vasculitis. J Am Acad Dermatol 1982, 7:359-363.
66. Choi H.J., Hann S.K. Livedo reticularis and livedoid vasculitis responding to PUVA therapy. J Am Acad Dermatol 1999, 40(2 Pt 1):204-207.
67. Lee J.H., Choi H.J., Kim S.M., Hann S.K., Park Y.K. Livedoid vasculitis responding to PUVA therapy. Int J Dermatol 2001, 40(2):153-157.
68. Tuchinda C., Leenutaphong V., Sudtim S., Lim H.W. Refractory livedoid vasculitis responding to PUVA: a report of four cases. Photodermatol Photoimmunol Photomed 2005, 21(3):154-156.
69. Ravat F.E., Evans A.V., Russell-Jones R. Response of livedoid vasculitis to intravenous immunoglobulin. Br J Dermatol 2002, 147(1):166-169.
70. Kreuter A., Gambichler T., Breuckmann F., Bechara F.G., Rotterdam S., Stücker M., et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 2004, 51(4):574-579.
71. Sobral Filho J.F., Valdek C.O.M., Rodrigues L.T.D. Tratamento de vasculopatia liveóide com imunoglobulina intravenosa. An Bras Dermatol 2008, 83(4):372-374.
72. Leclerc A., Braeken C., Marot L., Tennstedt D., Lachapelle M. La vasculite livédoïde. Traitement par ciclosporine: A propos de cinq cas. Lês Nouv Dermatologiques 2000, 19(4):356-360.
73. Yang C.H., Ho H.C., Chan Y.S., Liou L.B., Hong H.S., Yang L.C. Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen. Br J Dermatol 2003, 149(3):647-652.
74. Hölschermann H., Kohl O., Maus U., Dürfeld F., Bierhaus A., Nawroth P.P., et al. Cyclosporin A inhibits monocyte tissue factor activation in cardiac transplant recipients. Circulation 1997, 96(12):4232-4238.
75. Hölschermann H., Dürfeld F., Maus U., Bierhaus A., Heidinger K., Lohmeyer J., et al. Cyclosporine a inhibits tissue factor expression in monocytes/macrophages. Blood 1996, 88(10):3837-3845.
76. Schabbauer G., Schweighofer B., Mechtcheriakova D., Lucerna M., Binder B.R., Hofer E. Nuclear factor of activated T cells and early growth response-1 cooperate to mediate tissue factor gene induction by vascular endothelial growth factor in endothelial cells. Thromb Haemost 2007, 97(6):988-997.
77. Fernandes T.D. Hyperbaric medicine. Acta Méd Port 2009, 22(4):323-334.
78. Tsutsui K., Shirasaki F., Takata M., Takehara K. Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. Dermatology 1996, 192(2):120-124.
79. Chan Y.C., Valenti D., Mansfield A.O., Stansby G. Warfarin induced skin necrosis. Br J Surg 2000, 87:266-272.
80. Criado P.R., Rivitti E.A., Vasconcellos C., Valente N.Y.S., Costa Martins J.E. Manifestações Cutâneas das Trombofilias. An Bras Dermatol 2008, 83(6):491-506.
81. Francès C., Barete S. Difficult management of livedoid vasculopathy. Arch Dermatol 2004, 140(8):1011.
82. Heine K.G., Davis G.W. Idiopathic atrophie blanche: treatment with low-dose heparin. Arch Dermatol 1986, 122:855-856.
83. Jetton R.L., Lazarus G.S. Minidose heparin therapy for vasculitis of atrophie blanche. J Am Acad Dermatol 1983, 8:23-26.
84. Merli G.J., Groce J.B. Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P T 2010, 35(2):95-105.
85. Anglés-Cano E., de la Peña Díaz A., Loyau S. Inhibition of fibrinolysis by lipoprotein (a). Ann NY Acad Sci 2001, 936:261-275.
86. Peplow P.V. Glycosaminoglycan: a candidate to stimulate the repair of chronic wounds. Thromb Haemost 2005, 94:4-16.
87. Traumatann A., Seitz C.S. The complex clinical picture of side effects to anticoagulation. Med Clin N Am 2010, 94:821-834.
88. Toubi E., Shonfeld Y. Livedo reticularis as a criterion for antiphospholipid syndrome. Clin Rev Allergy Immunol 2007, 32(2):138-144.
89. Toubi E., Krause I., Fraser A., Lev S., Stojanovich, Rovensky J., et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005, 23:499-504.
90. Biggioggero M., Meroni P.L. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev 2010, 995:A299-A304.
91. Asherson R.A. New sunsets of the antiphospholipid syndrome in 2006: "PRE-APS" (probable APS) and microangiopathic syndromes ("MAPS"). Autoimmun Rev 2006, 6(2):76-80.